David McIntyre - Apr 14, 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Chief Financial Officer
Signature
/s/ David McIntyre
Stock symbol
IKT
Transactions as of
Apr 14, 2025
Transactions value $
$0
Form type
4
Date filed
4/16/2025, 04:06 PM
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +1.78M $0.00 1.78M Apr 14, 2025 Common Stock 1.78M $2.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on April 14, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment on each such vesting date.